washington: The Supreme Court Wednesday stayed for two days a lower court ruling that sought to limit access to the abortion pill mifepristone, ensuring the drug will remain widely available for as long as possible.
Justice in short order Samuel Alito announced that the adjournment would end at midnight on Friday, giving the court more time to consider the matter, though it could act until then.
That the court did not meet the earlier deadline suggests disagreement among the justices in its first major case about abortion access since a conservative majority struck down the constitutional right to abortion in June. Might be possible. It may also indicate that there may be dissatisfaction in the matter.
issue is the judge’s decision Matthew Kaczmarik of the Northern District of Texas, which in recent weeks invalidated the Food and Drug Administration’s approval of mifepristone, part of the most commonly used method for terminating pregnancies in the United States.
The court order slows down a chaotic and fast-moving landscape for mifepristone, marked by a controversial US District Court ruling and an appeals panel decision that further complicates the drug’s legal status.
Since the Supreme Court overturned Roe v. Wade, the landmark 1973 case, in June, the political and legal battle has centered on drugs used for abortions. In some conservative states, lawmakers have targeted the bullets.
Medication abortion, a two-drug regimen, is usually used in the first 12 weeks of pregnancy. The first drug, mifepristone, blocks progesterone, a hormone that allows pregnancy to develop, and the second, misoprostol, taken a day or two later, induces contractions and causes the uterus to expel its contents. helps in
The controversy began in Texas in November, when an umbrella group of medical organizations and some doctors who oppose abortion filed suit FDAchallenging the approval of the pill more than two decades ago.
In their lawsuit, anti-abortion groups claimed that the FDA did not follow proper protocols when it approved the drug in 2000. The groups said the agency had also ignored the dangers of the drug for years.
The FDA has vigorously contested those claims, saying the drug was appropriately approved more than 20 years ago and is very safe.
Justice in short order Samuel Alito announced that the adjournment would end at midnight on Friday, giving the court more time to consider the matter, though it could act until then.
That the court did not meet the earlier deadline suggests disagreement among the justices in its first major case about abortion access since a conservative majority struck down the constitutional right to abortion in June. Might be possible. It may also indicate that there may be dissatisfaction in the matter.
issue is the judge’s decision Matthew Kaczmarik of the Northern District of Texas, which in recent weeks invalidated the Food and Drug Administration’s approval of mifepristone, part of the most commonly used method for terminating pregnancies in the United States.
The court order slows down a chaotic and fast-moving landscape for mifepristone, marked by a controversial US District Court ruling and an appeals panel decision that further complicates the drug’s legal status.
Since the Supreme Court overturned Roe v. Wade, the landmark 1973 case, in June, the political and legal battle has centered on drugs used for abortions. In some conservative states, lawmakers have targeted the bullets.
Medication abortion, a two-drug regimen, is usually used in the first 12 weeks of pregnancy. The first drug, mifepristone, blocks progesterone, a hormone that allows pregnancy to develop, and the second, misoprostol, taken a day or two later, induces contractions and causes the uterus to expel its contents. helps in
The controversy began in Texas in November, when an umbrella group of medical organizations and some doctors who oppose abortion filed suit FDAchallenging the approval of the pill more than two decades ago.
In their lawsuit, anti-abortion groups claimed that the FDA did not follow proper protocols when it approved the drug in 2000. The groups said the agency had also ignored the dangers of the drug for years.
The FDA has vigorously contested those claims, saying the drug was appropriately approved more than 20 years ago and is very safe.